Muscle Memory After Treatment With Anabolic Substance Clenbuterol and Resistance Training in Humans

NCT05692856 | Unknown

• 1 other identifier: CLEN-MEM
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the project is investigate muscle memory and underlying mechanisms in humans following resistance training and use of the anabolic substance clenbuterol.

Conditions

Skeletal Muscle Physiology

Outcome Measures

Primary Outcomes (3)

• Fiber cross-sectional area

  Immunohistochemistry to determine fiber cross-sectional area

  The change in fiber cross-sectional is assessed at baseline, 8, 24 and 32 weeks

• Myonuclei

  Immunohistochemistry to determine number of myonuclei

  The change in myonuclei is assessed at baseline, 8, 24 and 32 weeks

• Skeletal muscle proteome

  Pathway enrichment analysis of the muscle proteome using mass-spectrometry based proteomics

  The change in the muscle proteome is assessed at baseline, 8, 24 and 32 weeks

Secondary Outcomes (5)

• Lean mass

  The change in lean mass is assessed at baseline, 8, 24 and 32 weeks

• Isometric muscle strength

  The change in maximal voluntary isometric contraction is assessed at baseline, 8, 24 and 32 weeks

• Dynamic muscle strength

  The change in 1-repetition maximum is assessed at baseline, 8, 24 and 32 weeks

• Sprint performance

  The change in sprint performance is assessed at baseline, 8, 24 and 32 weeks

• Satellite cells

  The change in satellite cells is assessed at baseline, 8, 24 and 32 weeks

Study Arms (2)

Clenbuterol

EXPERIMENTAL

Participants are randomized to daily ingestion of clenbuterol for a period of 8 weeks, with or without supervised resistance training.

Drug: Clenbuterol

Placebo

PLACEBO COMPARATOR

Participants are randomized to daily ingestion of placebo for a period of 8 weeks, with or without supervised resistance training.

Drug: Placebo

Interventions

Clenbuterol DRUG

Participants ingest 80 micrograms clenbuterol daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.

Clenbuterol

Placebo DRUG

Participants ingest placebo tablets daily during the initial 8-week period. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, an 8-week period with supervised resistance training is commenced, with no drug.

Placebo

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy men and women
• BMI of \<26 and normal ECG and blood pressure

You may not qualify if:

• Smoking
• Chronic disease,
• Use of prescription medication
• Pain due to current or previous musculoskeletal injury
• Resistance training more than once per week in the 12 months leading up to the intervention
• Current or previous use of prohibited anabolic substances

Sponsors & Collaborators

• Morten Hostrup, PhD: lead

Study Sites (1)

August Krogh Building

Copenhagen, 2100, Denmark

RECRUITING

MeSH Terms

Interventions

Clenbuterol

Intervention Hierarchy (Ancestors)

Ethanolamines; Amino Alcohols; Alcohols; Organic Chemicals; Amines

Central Study Contacts

Morten Hostrup

CONTACT

+4535321595; mhostrup@nexs.ku.dk

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: December 23, 2022
• First Posted: January 20, 2023
• Study Start: February 1, 2023
• Primary Completion: December 1, 2024
• Study Completion: August 1, 2025
• Last Updated: January 20, 2023

Record last verified: 2023-01

Locations

DK (1)